When a trial reports an objective response rate six times the comparator's, that figure travels. It is the one quoted in the press release, the one a patient's relative finds, and the one you will be asked about. It is also the least useful of the trial's three efficacy results, because response rate measures tumour shrinkage at a timepoint, not how long someone lives.
Have the ordering ready before the conversation. Overall survival is what the patient is asking about. Progression-free survival tells you about disease control and, indirectly, about time with symptoms controlled. Response rate tells you how likely the scan is to look better, which matters for symptoms driven by bulk but is not a survival claim. When all three point the same way, as they do in the small-cell result today, the conversation is easy. The habit matters for the far commoner case where response is impressive and survival is not.
- Lead with overall survival when a patient asks what a new drug does.
- Explain response rate as 'how likely the scan improves', not as a measure of living longer.
- Be explicit when a drug improves response and progression-free survival but not survival.
- Ask what the patient has already read before quoting any figure - they usually have the response rate.
- Give absolute medians alongside hazard ratios; a hazard ratio means little at the bedside.
Why it matters
The most quotable number in an oncology trial is usually the one least connected to how long the patient will live.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free